Pain symposium contribution
Our CSO Prof David Kendall is co-organizer of a British Pharmacological Society-sponsored symposium at the 2018 ELRIG Drug Discovery meeting in London in October (Read here). The symposium entitled “The opioid crisis, addiction and the search for more effective analgesics”, will bring together industrial and academic pain research experts and Prof Kendall will give a presentation on the potential of delta opioid receptor agonists in chronic pain therapy.
Pain symposium contribution
Our CSO Prof David Kendall is co-organizer of a British Pharmacological Society-sponsored symposium at the 2018 ELRIG Drug Discovery meeting in London in October (Read here). The symposium entitled “The opioid crisis, addiction and the search for more effective analgesics”, will bring together industrial and academic pain research experts and Prof Kendall will give a presentation on the potential of delta opioid receptor agonists in chronic pain therapy.
Latest news
View all
New publication in The Journal of Headache and Pain
PN6047 publication in The Journal of Headache and Pain strengthens PN6047 potential in migraine and headache disorders PharmNovo is pleased to announce that new preclinical research on PN6047 has been published in The Journal of Headache and Pain, adding to the growing body of scientific evidence supporting the potential of PN6047 beyond neuropathic pain.
Read more
Reports of broader therapeutic potential for PN6047
PharmNovo AB announces today new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine.
Read more
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more